JAKAVI 5 mg, tablet 56 tablets
Active ingredients: Ruxolitinib phosphate, Ruxolitinib
Commercialized according to BDPMDispensing in France: Prescription only
Tablet56 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JAKAVI 5 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 56 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 May 2014
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65291824CIP72732581CIP133400927325816Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PHOSPHATE DE RUXOLITINIBcomprimé | 6,6 mg · un comprimé | SA |
| RUXOLITINIBcomprimé | 5 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.